{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-007978","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.555955+00:00","generated_at":"2026-06-15T19:09:59.515312+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protalix Q1 net loss $3.1M on revenue decline; positive CHMP opinion for PRX-102","bullets":["Revenue from goods fell 43% to $5.1M; license and R&D revenue down 37% to $4.5M.","Net loss of $3.1M ($0.05/sh) vs $2.3M loss in Q1 2022; cash $33.0M.","Feb 24, 2023: CHMP positive opinion recommending EU approval of PRX-102 for Fabry disease.","First patient dosed in Phase I trial of PRX-115 (PEGylated uricase) for severe gout.","Voluntary delisting from Tel Aviv Stock Exchange effective March 22, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-007978","json":"https://secwatch.observer/filing/0001558370-23-007978.json","markdown":"https://secwatch.observer/filing/0001558370-23-007978.md","text":"https://secwatch.observer/filing/0001558370-23-007978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023007978/0001558370-23-007978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023007978/plx-20230504x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T19:09:59.515312+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f1f5f945250625abc85f0d82d456435c158a712","claim":"Protalix BioTherapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue Revenues from selling goods of $5.1 million and revenues from license and R&D services of $4.5 million, net income Net loss of approximately $3.1 million, EPS loss of $0.05 per share.","evidence_excerpt":"First Quarter 2023 Financial Highlights ● The Company recorded revenues from selling goods of $5.1 million during the three months ended March 31, 2023, a decrease of $3.9 million, or 43%, compared to revenues of $9.0 million for the three months ended March 31, 2022. The decrease resulted primarily from a decrease of $2.7 million in sales to Brazil and a decrease of $1.1 million in sales to Pfizer, both resulting from timing differences. ● The Company recorded revenues from license and R&D services of $4.5 million for the three months ended March 31, 2023, a decrease of $2.6 million, or 37%, compared to revenues of $7.1 million for the three months ended March 31, 2022. Revenues from license and R&D services are comprised primarily of revenues the Company recognized in connection with the Chiesi Agreements. ● Cost of goods sold was $3.1 million for the three months ended March 31, 2023, a decrease of $2.9 million, or 48%, from cost of goods sold of $6.0 million for the three months en","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023007978/0001558370-23-007978-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"Revenues from selling goods of $5.1 million and revenues from license and R&D services of $4.5 million"},{"label":"Net income","value":"Net loss of approximately $3.1 million"},{"label":"EPS","value":"loss of $0.05 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}